Ibio Inc (IBIO)
$1.51 0.05 (3.42%)
17:00 EST IBIO Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 24.07M
PE Ratio -0.89
Volume (Avg. Vol.) 6.77M
Day's Range 1.40 - 1.53
52-Week Range 0.11 - 7.45
Dividend & Yield N/A (N/A)
IBIO Stock Predictions, Articles, and Ibio Inc News
- From InvestorPlace
- From the Web
One of the more intriguing high-risk, high-reward ideas in the Covid-19 space, IBIO stock had an opportunity to distinguish itself. But with the vaccine race heating up, the dangers outweigh the possibilities.
iBio’s first-quarter included steep losses and not much else. If IBIO stock is to rise to $2, investors need some good news to chew on.
The latest in IBIO news: stay away from IBIO stock, which has over-issued shares to survive. The stock remains below the average issue price.
The latest iBio news isn't good. It's taken too long for IBIO to develop a coronavirus vaccine and now the opportunity has disappeared.
iBio has a huge vertical farming facility and a couple of high-potential vaccine candidates, which should offer hope to IBIO stock holders.
Investor interest a unique production system isn’t enough to make buying IBIO stock a worthwhile move at this time.
IBIO stock has been hit hard by its apparent failure to produce the first COVID-19 vaccine, but that’s a simplistic view of iBio’s prospects.
Here are a handful of micro-cap stocks that are oversold and attractive for risk-taking investors. These also have high dividend yield.
With the viable candidate pool for novel coronavirus vaccines shrinking, this angle is probably closed to IBIO stock. However, speculators still have a shot with the therapeutic approach.
An investment in IBIO stock is a bet on the company’s unique FastPharming system to create medications and therapies of all sorts.
Since hitting $1.70 on Aug. 21, IBIO stock has gone sideways. With little on the news front over the past seven weeks, it’s easy to see why.
Most bulls buying into IBIO stock the past few months are underwater. But that short-term pain may have finished.
By Joel Baglole
Since peaking at $7.45 per share in July, iBio's stock price has fallen further from its 52-week high as hopes fade for the company to make a meaningful impact towards a cure for Covid-19. Today, IBIO stock is trading at just over $2 a share, about the same level it was at in early March of this year. Investors would be wise to sell this stock now before its price falls even more in coming weeks.
Investors pondering how a company with a history of moving back-and-forth between micro- and small-cap territory could adequately compete against more well-heeled rivals were right to express those concerns and IBIO stock validated those worries.
IBIO stock will continue to ebb and flow as the pandemic rages on. Day traders should look out for positive clinical trial news as a buy-in signal.
Navellier RatingsPowered by Portfolio Grader